PHO-COG-FALLON-ACNS0332; Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotrectinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: medulloblastoma | pineoblastoma
  • Age: Between 3 - 21 Years
  • Gender: Male or Female

Inclusion Criteria
Histologically confirmed diagnosis of medulloblastoma
Meets 1 of the following criteria: M0 medulloblastoma with > 1.5 cm^2 residual tumor, M+ medulloblastoma, M0 or M+ supratentorial PNET (including pineoblastoma), Diffusely anaplastic medulloblastoma with any M-stage or residual tumor
Must have undergone stereotactic biopsy or attempted neurosurgical resection of the tumor within the past 31 days
Karnofsky performance status (PS) 30-100% (for patients > 16 years of age) OR Lansky PS 30-100% (for patients ? 16 years of age)
Life expectancy > 8 weeks
Exclusion Criteria
pregnant or nursing

Recruitment Status

Closed
Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

Contact Us

If you need help finding a study or have any questions, please contact us at inhealth@iu.edu or by phone at (888) 264-0005.